EIP
PFE icon

Easterly Investment Partners’s Pfizer PFE Stock Holding History

Easterly Investment Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
48,273
-33,600
-41% -$879K 0.06% 187
2026
Q1 		$2.27M Sell
81,873
-43,555
-35% -$1.16M 0.17% 84
2025
Q4 		$3.12M Buy
125,428
+36,110
+40% +$911K 0.19% 103
2025
Q3 		$2.28M Buy
89,318
+18,600
+26% +$459K 0.15% 116
2025
Q2 		$1.71M Buy
70,718
+50
+0.1% +$1.17K 0.12% 122
2025
Q1 		$1.79M Buy
70,668
+51,168
+262% +$1.34M 0.15% 118
2024
Q4 		$517K Buy
19,500
+200
+1% +$5.42K 0.04% 171
2024
Q3 		$559K Hold
19,300
– – 0.04% 175
2024
Q2 		$540K Sell
19,300
-813
-4% -$22.4K 0.05% 170
2024
Q1 		$558K Sell
20,113
-47,243
-70% -$1.31M 0.04% 177
2023
Q4 		$1.94M Sell
67,356
-338,645
-83% -$10.2M 0.21% 108
2023
Q3 		$13.5M Buy
406,001
+1,295
+0.3% +$45.8K 1.48% 15
2023
Q2 		$14.8M Buy
404,706
+137,180
+51% +$5.34M 1.31% 21
2023
Q1 		$10.9M Sell
267,526
-2,865
-1% -$124K 0.96% 39
2022
Q4 		$13.9M Sell
270,391
-13,334
-5% -$639K 1.2% 31
2022
Q3 		$12.4M Sell
283,725
-205,322
-42% -$9.98M 1.19% 27
2022
Q2 		$25.6M Sell
489,047
-167,487
-26% -$8.54M 2.28% 4
2022
Q1 		$34M Buy
656,534
+349,682
+114% +$18.1M 2.57% 3
2021
Q4 		$18.1M Sell
306,852
-152,233
-33% -$7.54M 1.32% 24
2021
Q3 		$19.7M Buy
459,085
+309,005
+206% +$13.7M 1.34% 21
2021
Q2 		$5.88M Sell
150,080
-445,785
-75% -$17.3M 0.69% 39
2021
Q1 		$21.6M Buy
595,865
+58,936
+11% +$2.09M 2.58% 20
2020
Q4 		$19.8M Sell
536,929
-2,180,284
-80% -$80M 2.73% 16
2020
Q3 		$94.6M Buy
2,717,213
+386,617
+17% +$13.6M 3.75% 9
2020
Q2 		$72.3M Sell
2,330,596
-89,130
-4% -$3.03M 3.28% 12
2020
Q1 		$74.9M Buy
2,419,726
+1,733,096
+252% +$59.1M 3.32% 15
2019
Q4 		$25.5M Buy
686,630
+633,002
+1,180% +$22.5M 0.72% 38
2019
Q3 		$1.83M Sell
53,628
-3,126,595
-98% -$114M 0.05% 50
2019
Q2 		$131M Sell
3,180,223
-2,124,153
-40% -$84.3M 3.28% 14
2019
Q1 		$214M Buy
+5,304,376
New +$212M 5.16% 3

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

Easterly Investment Partners's PFE Position: Q2 2026 in Review

Easterly Investment Partners reduced its Pfizer (PFE) stake by 41% in Q2 2026, selling an estimated $879K and leaving 48,273 shares worth $1.16M. The position accounts for 0.06% of the portfolio, ranked #187.

Easterly Investment Partners first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $214M in Q1 2019. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Easterly Investment Partners held 48,273 shares of Pfizer worth $1.16M as of Q2 2026.
  • Easterly Investment Partners sold 33,600 Pfizer shares in Q2 2026, an estimated $879K.
  • Pfizer made up 0.06% of Easterly Investment Partners's portfolio in Q2 2026, its #187 holding.
  • Easterly Investment Partners first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
  • Easterly Investment Partners's Pfizer position peaked at $214M in Q1 2019.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Easterly Investment Partners's 13F filing for Q2 2026, filed 23 Jul 2026.